Glen Harbor Capital Management’s Esperion Therapeutics ESPR Stock Holding History

Glen Harbor Capital Management’s Portfolio ESPR Stock Details ESPR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	$339K	Sell	9,240 -84	-0.9%	-$3.33K	0.01%	842
2019 Q2	$434K	Sell	9,324 -2,436	-21%	-$114K	0.01%	748
2019 Q1	$472K	Buy	11,760 +364	+3%	+$16.3K	0.01%	698
2018 Q4	$524K	Sell	11,396 -2,324	-17%	-$112K	0.01%	599
2018 Q3	$609K	Buy	13,720 +11,900	+654%	+$546K	0.01%	639
2018 Q2	$71K	Sell	1,820 -15,848	-90%	-$801K	﹤0.01%	1182
2018 Q1	$1.28M	Buy	17,668 +13,384	+312%	+$983K	0.03%	364
2017 Q4	$282K	Sell	4,284 -3,108	-42%	-$167K	0.01%	857
2017 Q3	$371K	Sell	7,392 -896	-11%	-$43.2K	0.01%	690
2017 Q2	$384K	Sell	8,288 -2,800	-25%	-$103K	0.01%	667
2017 Q1	$391K	Hold	11,088	–	–	0.01%	617
2016 Q4	$139K	Buy	+11,088	New	+$132K	﹤0.01%	800

Other funds holding ESPR

Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return

Meditor Group Hamilton, Bermuda $48.1M AUM 38.67% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

PCM

Pentwater Capital Management Naples, Florida $16.4B AUM 55.44% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

RPAM

Rhenman & Partners Asset Management Stockholm, Sweden $1.06B AUM 52.03% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

Glen Harbor Capital Management's ESPR Position: Q3 2019 in Review

Glen Harbor Capital Management reduced its Esperion Therapeutics (ESPR) stake by 0.9% in Q3 2019, selling an estimated $3.33K and leaving 9,240 shares worth $339K. The position accounts for 0.01% of the portfolio, ranked #842.

Glen Harbor Capital Management first reported a position in ESPR in Q4 2016 and has held it in 12 quarters since. The position peaked at $1.28M in Q1 2018. 152 funds tracked by Wall St. Rank hold ESPR as of Q3 2019.

Glen Harbor Capital Management held 9,240 shares of Esperion Therapeutics worth $339K as of Q3 2019.
Glen Harbor Capital Management sold 84 Esperion Therapeutics shares in Q3 2019, an estimated $3.33K.
Esperion Therapeutics made up 0.01% of Glen Harbor Capital Management's portfolio in Q3 2019, its #842 holding.
Glen Harbor Capital Management first reported a position in Esperion Therapeutics in Q4 2016 and has held it in 12 quarters since.
Glen Harbor Capital Management's Esperion Therapeutics position peaked at $1.28M in Q1 2018.
152 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q3 2019.

Based on Glen Harbor Capital Management's 13F filing for Q3 2019, filed 13 Nov 2019.